Company news

Amarantus Bioscience Holdings, Inc. (OTC:AMBS) news

Amarantus Bioscience Holdings, Inc. news releases on 6ix. Latest, Apr 16, 2018: Amarantus Appoints Michael T. Ropacki, PhD as Chief Medical Advisor…

Amarantus Bioscience Holdings, Inc. (OTC:AMBS) news

Press releases — page 3

Amarantus Appoints Michael T. Ropacki, PhD as Chief Medical Advisor for Alzheimer's Blood Diagnostic LymPro Test Program

Amarantus to Present at The Microcap Conference in NYC

Amarantus Re-acquires Rights to Alzheimer's Blood Diagnostic LymPro Test

Amarantus Appoints Barney Monte as Interim COO/CFO and Promotes Brian Harvey to Chief Regulatory Advisor

Amarantus Relocates Headquarters to WeWork at 110 Wall St. in New York City

Amarantus Completes Tender Exchange of Convertible Securities; CEO attending CNBC's Healthy Returns conference in New York City

Elto Pharma Receives Notice of Allowance in Australia for Patent Covering Eltoprazine in the Treatment of Parkinson's Levodopa-induced Dyskinesia

Elto Pharma to Present and Participate in Neuroscience Panel at Sachs BioCapital USA Forum

MANF Therapeutics Announces the Issuance of U.S. Patent #9,891,231

Amarantus Enters into Definitive Agreements for up to $1.5 Million in Funding

Amarantus Subsidiary MANF Therapeutics Announces Positive Independent Peer-Reviewed Pre-Clinical Data for MANF in Parkinson’s Disease

Amarantus Subsidiary Cutanogen Corporation Announces Issuance of US Patent 14/299,480 Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS

Amarantus Provides Update on Capital Restructuring and Announces Participation in RESI JPM 2018

Amarantus Subsidiary Cutanogen Corporation Announces Patent Issuance in Hong Kong Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS

AMBS Enters into Binding LOI to Re-acquire Rights to LymPro, MSPRecise and NuroPro

Amarantus Subsidiary MANF Therapeutics Announces Patent Issuances in Europe and China Covering MANF as a Treatment and Biomarker in Diabetes and Publication of MANF Human Pre-Diabetes and Diabetes Biomarker Data

Amarantus Subsidiary MANF Therapeutics Announces Retinal Patent Issuances in Europe Covering MANF & CDNF and Positive Data for MANF in Glaucoma

Amarantus Subsidiary MANF Therapeutics Announces Issuance of Japanese Patent Covering Therapeutic Use of MANF in Treatment of Parkinson's Disease

Amarantus Subsidiary MANF Therapeutics Announces Publication in Science Magazine of Positive Animal Data for MANF in Treatment of Retinal Damage and Issuance of Retinal Patent in Japan Covering MANF and CDNF

Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from U.S. Patent & Trademark Office Covering MANF Treatment of Diabetes

Amarantus Subsidiary Elto Pharma Announces the Issuance of Patents in Singapore and New Zealand Covering Treatment of Parkinson’s LID

Amarantus Subsidiary Elto Pharma Receives Notice of Allowance for European Patent Application Covering Method of Treating Cognitive Impairment Associated with Alzheimer’s Disease and Parkinson’s disea

Amarantus Provides Comprehensive Corporate Update •

Amarantus Enters into Forbearance and Capital Restructuring Agreements with Holders of Secured Debt, Convertible Preferred Stock and Warrants

Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focus on Ophthalmology

Amarantus Provides Update on Restructuring Efforts and Letter of Intent with SeD Biomedical, Inc.

Amarantus Enters into a Letter of Intent to Acquire Certain Biotechnology Assets from SeD BioMedical Inc.

Amarantus Announces Passing of Biotechnology Legend Dr. Joseph Rubinfeld

Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns

Avant Diagnostics Presented Data on TheraLink® Pancreatic Cancer Assay at the International Symposium on Pancreas Cancer 2016

Amarantus Announces cGMP Manufacturing Readiness for Its Engineered Skin Substitute (ESS) Program at Lonza Walkersville

Amarantus Completes Sale of Diagnostics Division, Announces Fiscal Year 2015 and First Quarter 2016 Financial Results

OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference

Amarantus Announces Upcoming Investor Presentations

Avant Diagnostics Simultaneously Completes Acquisitions of Amarantus Diagnostics and Theranostics Health

Retired American Burn Association President Dr. David Ahrenholz to Present on Engineered Skin Substitute (ESS) at the Vatican's Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact

Amarantus Announces Capital Infusion

Amarantus Announces Cancellation of Special Meeting of Shareholders

Avant Diagnostics, Amarantus Diagnostics and Theranostics Health Provide Updated Information for Conference Call to Discuss Business Combination

Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health

Amarantus Diagnostics and Avant Diagnostics to Form 3-Way Business Combination with Theranostics Health

Amarantus Appoints Brian E. Harvey, MD PhD to Strategic Advisory Board

Amarantus Receives Notices of Allowance from European Patent Office for MANF and CDNF in the Treatment of Retinal Disorders

Amarantus and Lonza Walkersville, Inc. Provide Update on cGMP Manufacturing Readiness for the Engineered Skin Substitute (ESS) Program

Amarantus Announces $3M Capital Infusion

Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia

Amarantus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference

Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa

Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)

Amarantus Announces Issuance of Chinese Patent Covering Use of MANF for the Treatment of Parkinson's Disease